Hepatitis C (chronic) - ledipasvir-sofosbuvir [ID742]: committee papers 1

Table of Contents

01 - Pre-Meeting Briefing prepared by NICE

02 - Submission from the technology manufacturer - Gilead Sciences

03 - NICE request to the Company for clarification on their submission

04 - Appendix to the clarification letter

05 - Company clarification response

06 - Consultee submission - Hepatitis C Trust

07 - Consultee submission - Liver for Life

08- Consultee submission - British Society for Gastroentology

09- Clinical expert personal perspective - Cramp

10- Clinical expert personal perspective - Harris

11- Patient expert personal perspective - Hall

12 - Evidence Review Group report prepared by Scharr

13 - Evidence Review Group report Factual error check

14 - Erratum to the Evidence Review Group report

15 - Addendum to the Evidence Review Group Report

16 - Addendum two to the Evidence Review Group Report

This page was last updated: 23 July 2015